Mizuho Initiates Erasca (ERAS) With ‘Outperform’ Rating and $16 PT
On January 27, 2026, Mizuho initiated coverage of Erasca, Inc. (NASDAQ:ERAS) with an ‘Outperform’ rating and a $16 price target.
Erasca Inc. (ERAS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Vivo Capital Albert Cha And Frank Kung | 9,273,428 | $34,497,152 | 2.23% | |
| 2. | Siren L.L.C. Raymond Debbane | 8,757,249 | $32,576,966 | 0.97% | |
| 3. | Soleus Capital Guy Levy | 2,162,162 | $8,043,243 | 0.3% | |
| 4. | SilverArc Capital Devesh Gandhi | 1,317,584 | $4,901,412 | -4% | 0.68% |
| 5. | Renaissance Technologies Jim Simons | 850,100 | $3,162,372 | -17% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.27 | 80,000 | $181,920.00 | 573,974 | 2024-05-21 | Filing | |
| $1.85 | 10,000 | $18,480.00 | 20,000 | 2023-12-06 | Filing | |
| $1.72 | 278,150 | $478,418.00 | 12,899,360 | 2023-12-06 | Filing | |
| $1.69 | 721,850 | $1,217,760.95 | 12,899,360 | 2023-12-05 | Filing | |
| $1.66 | 30,000 | $49,785.00 | 493,974 | 2023-12-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.59 | 120,000 | $670,812.00 | 25,076 | 2026-01-07 | Filing | |
| $18.77 | 200,000 | $3,753,000.00 | 10,305,553 | 2021-07-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,729,436 | $84,553,502 | 2.27% | |
| 2. | 15,597,330 | $58,022,066 | 0% | |
| 3. | 12,812,156 | $47,661,220 | 0% | |
| 4. | 6,174,642 | $22,969,668 | 0% | |
| 5. | 4,926,335 | $18,330,444 | 0% |
News See All
11 Best Performing Stocks in the Last 12 Months
The year 2025 was not just another year but a period marked by sharp shifts in technology, geopolitics, and trade policy, often driving markets in surprising ways, according to Reuters' year-end report...
Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models
Erasca Inc. (NASDAQ:ERAS) is one of the new stocks on the rise. On January 27, Guggenheim increased its price target for Erasca from $5 to $12 with a Buy rating.
10 New Stocks on the Rise
On January 21, Lynn Martin, NYSE president, joined CNBC's Sara Eisen to discuss the IPO landscape for 2026.
Erasca (ERAS) Soars 42% on Bullish Rating, PT Upgrade
Meanwhile, HC Wainwright also gave a price target of $11 versus $6 previously, with a “buy” recommendation, following Erasca Inc.’s (NASDAQ:ERAS) positive preliminary results from the clinical study...
Erasca (ERAS) Touches 3-Year High as 4 Analysts Go Bullish; Gets 267% PT Hike
Erasca notched another three-year high anew on Thursday, as investor sentiment continued to be fueled by four investment firms’ bullish outlooks for its stock, with the company earning a price target...
Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike
Erasca extended gains to a second day on Wednesday to hit a new three-year high, as investors continued to load up on shares after earning 267 percent and 83 percent higher price targets from two investment...
Erasca (ERAS) Climbs to 3-Year High as Analyst Hikes PT by 83%
The upgrade followed Erasca Inc.’s (NASDAQ:ERAS) presentation of preliminary clinical data at the 44th Annual JP Morgan Healthcare Conference on Tuesday, saying that it saw two confirmed partial responses...
Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results
On November 14, 2025, Erasca, Inc. (NASDAQ:ERAS) saw Guggenheim’s analyst Michael Schmidt reiterate a “Buy” rating with a $5 price target, following the company’s Q3 2025 results.
12 Hot Penny Stocks to Invest in Right Now
Goldman Sachs Asset Management portfolio manager Greg Tuorto appeared on CNBC on November 17, 2025.
Hedge Fund Resource Center Billionaire Hedge Funds
